Corporate Strategy

Chronic pain continues to be significantly undertreated in many patients, resulting in increased health care utilization costs and poor quality of life outcomes. Increasingly, patients, advocacy groups, pain societies, the Joint Commission on Accreditation of Health Care Organizations and the media are highlighting the limitations of pain management and are demanding changes in the medical system.

TheraQuest’s business strategy is to use its considerable pain treatment knowledge and development expertise to identify, develop and commercialize product candidates with strong market potential that have significantly lower development costs and clinical, regulatory and commercial risk profiles than new chemical entities.

TheraQuest’s core strength is its pain drug development expertise. Our team possesses considerable experience and knowledge in the design and conduct of clinical trials in analgesia and rheumatology, including cancer pain, neuropathic pain, low back pain, osteoarthritis and myofascial pain. The TheraQuest team has contributed to the development of numerous analgesics approved in the United States in the past 20 years.

A key to TheraQuest’s success is our ability to identify new product opportunities for which significant intellectual property can be generated. We have extensive knowledge of the pain products market and compounds to treat various pain indications. We anticipate that we will continue to grow our pipeline by identifying compounds such as:

• Novel oral extended release dosage forms of drugs not previously given by orally
• New pain indications for drugs approved for other uses
• Drugs for which we can obtain orphan drug market exclusivity
• Novel transdermal formulations of drugs not previously applied to the skin
• Drugs approved outside the U.S. for which we pursue FDA approval